McPartlin Andrew, Grimaldo Claudia, Lyons Jeanette, Burke Daniel, Mitra Sandip, Choudhury Ananya
The Christie NHS Foundation Trust , Manchester , UK.
The Christie NHS Foundation Trust , Manchester , UK ; The University of Manchester , Manchester , UK.
Clin Kidney J. 2014 Dec;7(6):593-4. doi: 10.1093/ckj/sfu097. Epub 2014 Sep 16.
We report on the successful treatment of small-cell prostate cancer in a patient undergoing haemodialysis. The therapeutic regimen included 300 mg/m(2) of carboplatin and 50 mg/m(2) of etoposide coupled with radical radiotherapy. Adjustments to the patient's haemodialysis prescription included the use of high flux, a larger dialyser surface area and an increased dialysis time. The parameters used aided tolerance to the drug, allowing the delivery of safe, effective treatment. At an interval of over 12 months post-treatment the patient shows no clinical evidence of recurrent disease. This case provides evidence to encourage the use of chemotherapy in otherwise potentially undertreated haemodialysed patients.
我们报告了1例接受血液透析患者的小细胞前列腺癌的成功治疗。治疗方案包括300mg/m²的卡铂和50mg/m²的依托泊苷，联合根治性放疗。对患者血液透析处方的调整包括使用高通量、更大的透析器表面积和增加透析时间。所采用的参数有助于提高对药物的耐受性，从而能够进行安全、有效的治疗。治疗后间隔超过12个月，患者无疾病复发的临床证据。该病例为鼓励在其他可能治疗不足的血液透析患者中使用化疗提供了依据。
